Tocilizumab, for instance, blocks IL6/STAT3 signaling and reduces the cancer/inflammation epigenetic IL6/STAT3/NF-kB positive feedback loop, which is of immense therapeutic utility for patients with resistant triple-negative breast cancer [172]. This evidence concerns the gene IL6 and triple-negative breast carcinoma.